Coya Therapeutics, Inc. 8-K

What Happened
Coya Therapeutics, Inc. (COYA) filed a Form 8‑K on January 20, 2026 to report other events disclosed in a letter to stockholders. The company announced an unaudited cash balance of $46.8 million as of December 31, 2025 and said that this cash is projected to provide a runway into the second half of 2027. Coya also stated it expects a topline data readout from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027.

Key Details

• Filed: Form 8‑K (Item 8.01) dated January 20, 2026, disclosing a letter to stockholders.
• Cash balance: $46.8 million (unaudited) as of December 31, 2025.
• Cash runway: Projected to extend into the second half of 2027.
• Clinical milestone: Topline ALSTARS Phase 2 trial data expected in Q1 2027.

Why It Matters
These facts give investors a snapshot of Coya’s near‑term financial position and clinical timeline. The reported cash balance and stated runway indicate how long the company expects to fund operations without immediate additional financing, while the upcoming ALSTARS Phase 2 topline readout is a material clinical milestone that could affect the company’s development progress and investor interest.